The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...

Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition impacts millions globally, with a 2023 analysis by DelveInsight reporting ...

Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock has reached its 52-week low, trading at $785.31. This price level reflects a subtle yet notable decline of 0.43% over the past year, indicating a ...

TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11 ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and ...

Regeneron Pharmaceuticals and Sanofi said the U.S. Food and Drug Administration has accepted their resubmitted application seeking expanded approval of the blockbuster anti-inflammatory drug ...

Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN), a leading biotechnology company, finds itself at a critical juncture as it navigates challenges to its flagship product while ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 2.71% to $782.51 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.60% ...

Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick ...